Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Is there any association between vitamin D receptor polymorphisms and acute myeloid leukemia?

Date

08 Oct 2016

Session

Poster Display

Presenters

Ali Esfahani

Citation

Annals of Oncology (2016) 27 (6): 313-327. 10.1093/annonc/mdw375

Authors

A. Esfahani1, Z. Ghoreishi2

Author affiliations

  • 1 Hematology And Oncology Research Center, Tabriz University of Medical Sciences, 5166614711 - Tabriz/IR
  • 2 Nutrition Research Center, Tabriz University of Medical Sciences, 5166614711 - Tabriz/IR
More

Resources

Abstract 3801

Background

Vitamin D receptor (VDR) can influence cancer development through binding with vitamin D. various studies examined the possible association of VDR polymorphism with the risk of solid tumors. In this study, the association of VDR polymorphism with acute myeloid leukemia (AML) and its possible effect on treatment outcomes was investigated for the first time.

Methods

VDR polymorphisms (FokI, BsmI, TaqI and ApaI) were compared between eligible patients with AML and control of healthy people using the PCR-RFLP procedure. Then, the effect of VDR polymorphisms on complete remission was examined.

Results

133 patients with AML (76 male, 57 female; mean age: 42.27± 15.84) and 300 control (173 male, 127 female; mean age: 41.55± 6.70) were enrolled. The frequency of VDR gene polymorphisms in both study groups were summarized in the Table 1. Thirty percent of the patients who achieved CR had TT genotype, while remaining 70% had TC genotype. The distribution of TaqI polymorphism in the patients without CR was as follows: 55% TT, 31% TC, and 14% CC; Therefore TaqI polymorphism was associated with CR. Table 1- The differences of VDR gene polymorphisms between patients with AML and control.

VDR gene polymorphisms Patients with AML (n = 133) Control (n = 300) P value
FokI
FF 62.3 49.7
Ff 29.2 33
ff 8.5 17.3 .017
BsmI
BB 15.6 37
Bb 41 53.7
bb 43.4 9.3 < .001
TaqI
TT 43 31.3
TC 44.7 56.3
CC 12.3 12.3 .072
ApaI
AA 67.8 43
Aa 27.3 36
aa 5 21 < .001

P value was calculated based on Fisher's exact test.

Conclusions

Like solid tumors, there is a significant association between VDR polymorphism and AML and TaqI polymorphism was associated with complete remission in patients with AML.

Clinical trial identification

Legal entity responsible for the study

Tabriz University of Medical Sciences, Tabriz, Iran

Funding

Tabriz University of Medical Sciences, Tabriz, Iran

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings